Rallybio has dosed the first subject in a trial of a potential treament for foetal and neonatal alloimmune thrombocytopaenia (FNAIT).

Annovis Bio has commenced the treatment of subjects in a Phase III clinical trial of buntanetap in treating early Alzheimer's ...

"We are pleased to report that the first subject in the subacute cohort of our Phase 1b/2a clinical trial in traumatic SCI has been enrolled and dosed. We believe that the protocol amendment will ...

After disease progression following the most recent treatment, the patient was enrolled in the clinical trial. Following infusion ... observed in the first subject further reinforce our confidence ...

Supreme Court's Justice Jamal Mandokhail on Wednesday raised question regarding the scope of the Army Act's jurisdiction, ...

U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for priority review with a PDUFA date of July 22, 2025 ...

Trials in China usually recruit patients faster than in the west because of the country’s large pool of people who have not yet taken drugs for their condition and who are keen to participate in ...

Financial writer advises caution on Jyong Biotech Ltd. IPO due to high debt, legal issues, and FDA challenges. Click for my ...

Aclaris' stock has dropped nearly 70% since September 2023, reflecting its history of failures and dissipations. Explore more ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ...